Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data
about
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of micePhysiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to HypoxiaLapatinib for breast cancer: a review of the current literature.Targeting tyrosine-kinases in ovarian cancer.HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomasLapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
P2860
Q33395016-F04EF716-18C5-49BB-A766-A774F08E83A6Q34291564-EC0279E2-4CD4-4425-A7B6-204FD30221ECQ34977187-DAE13AAE-D68C-41FC-993F-7929A8ED9CDCQ35222202-29D3C6AB-2A8F-4F0B-9646-48D053FBAABBQ35582767-9A15F29D-A149-4FEF-A4D7-0BE7297170D9Q35708124-E7E23E99-870E-4D6A-B998-C61C72B90879Q35946822-C7C9ACDF-D227-499E-B781-9BEDF01BCFC7Q35960779-E5A7C261-5FB8-4A53-A859-A7DB9E884666Q36411053-0BB1179F-45E1-47E3-AAE8-DB9A199E9EFBQ37498669-E76CF04F-7A4C-4345-97D1-CE271D8C34D8Q37653867-12777894-92F0-4D85-9893-4DF4F1E997D6Q37810946-620A48ED-F189-496D-909F-00B35D332544Q38118388-4FC4A738-4E3D-4116-BD11-CEBBE54815F2Q38735527-19CBFB56-0BD9-4C35-8C2F-AF65CE189515Q38848383-C923969A-4A30-407B-8B4D-7C91907360E7Q39031326-FBE1007B-CE23-48E2-861B-8AD87372328FQ39705093-D0261D7F-79C9-40E0-BAEA-AC9F82213E02Q39805970-2E4301A7-E000-40EF-A667-2010C33F8EE3Q54520474-D3AD9FC6-AF58-4AAA-BBE4-7075F1E68413
P2860
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@ast
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@en
type
label
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@ast
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@en
prefLabel
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@ast
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@en
P2093
P2860
P1476
Evaluation of lapatinib and to ...... nd phase I clinical trial data
@en
P2093
Alex A Adjei
Charles Erlichman
Joel M Reid
Julian R Molina
Karen S Flatten
Kevin M Koch
Marina Gálvez-Peralta
Robert Friedman
Robert J Mullin
Roxanne C Jewell
P2860
P304
P356
10.1158/1078-0432.CCR-08-0415
P407
P577
2008-12-01T00:00:00Z